Amylyx price target raised to $32 from $27 at Mizuho

Mizuho analyst Graig Suvannavejh raised the firm’s price target on Amylyx to $32 from $27 and keeps a Buy rating on the shares. The analyst’s updated model now includes the folding in of AMX0035 related revenue in two new indications, progressive supranuclear palsy and Wolfram syndrome. That said, the firm’s primary and near-term focus for Amylyx remains the announcement of top-line Phase 3 PHOENIX data evaluating Relyvrio for the treatment of amyotrophic lateral sclerosis.